Table 3. Summary of 1-Way and Probabilistic Sensitivity Analysesa.
| Variable | Cost (95% CI), $ | QALYs (95% CI) | ICERb | Probability of cost-effectiveness, % |
|---|---|---|---|---|
| HR for progression to radiation therapy | ||||
| 1.0 | 130 695 (100 439-160 950) | 1.49 (1.20-1.78) | Dominated | 0 |
| 0.75 | 110 309 (84 772-135 845) | 1.66 (1.34-1.98) | Dominant | 79 |
| 0.5 | 85 947 (66 050-105 843) | 1.87 (1.50-2.24) | Dominant | 92 |
| Cost of PRT | ||||
| 50% | 86 554 (66 516-106 591) | 1.78 (1.43-2.13) | Dominant | 90 |
| 10% | 80 275 (61 691-98 858) | 1.78 (1.43-2.13) | Dominant | 91 |
| Free | 78 440 (60 281-96 599) | 1.78 (1.43-2.13) | Dominant | 92 |
Abbreviations: HR, hazard ratio; ICER, incremental cost-effectiveness ratio; PRT, prostate radiation therapy; QALYs, quality-adjusted life-years.
a
The 95% CIs were calculated by rerunning the model 10 000 times with repeated Monte Carlo sampling with replacement from distributions of all input parameters.
b
A strategy was classified as dominant if it was associated with higher QALYs at lower costs than the alternative and dominated if it was associated with fewer QALYs at higher costs than the alternative.